OneSkin

Big pharma enters senolytic drug discovery programme

Latest articles

Exclusive video interview with Erin Sharoni of JUVICELL

We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni. Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...

New aging clock is a key longevity tool

A new aging clock that's close to the theoretical limit of accuracy boasts unprecedented precision and offers new insights into how the aging process...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

Exclusive video interview with Erin Sharoni of JUVICELL

We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni. Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...
OneSkin

Japanese pharma Taisho teams with Insilico to discover novel molecules that will tackle aging.

It was announced today that Taisho Pharmaceutical and Insilico Medicine have entered into a research collaboration to identify novel therapeutics against aging.

Longevity.Technology: We have reported on several Insilico news stories this year and CEO Alex Zhavoronkov has teased “several major announcements during Q4 this year.” Today’s announcement is doubly-exciting, as it spotlights an AI company partnering with a pharmaceutical company for both target discovery and small molecule generation and the targets are senolytics-focused.

Insilico Medicine will use both the target discovery and generative chemistry parts of its Pharma.AI platform in this collaboration. It will use its proprietary Pandomics Discovery Platform to identify novel targets for senolytic drugs and Chemistry42 platform for a molecular generation.

With the aim of extending the human healthspan, this collaboration brings together Insilico’s advanced AI technologies in drug discovery with Taisho’s drug development experience. Taisho has already dipped its toe in the Longevity pool; the HIF-PH inhibitor recently licensed by BioAge was also developed by them.

“We’re delighted to collaborate with Taisho pharmaceutical, a well-recognized leader in the pharmaceutical industry and healthcare sector,” said Jimmy Yen-Chu Lin, PhD, CEO of Insilico Medicine Taiwan, a fully-owned subsidiary of Insilico Medicine.

“It is believed that aging is a universal phenomenon that we cannot stop,” he added. “However, emerging scientific evidence has shown that one may be able to reverse some of the age-associated processes. Through this collaboration, we will adopt our AI-powered drug discovery suites together with Taisho’s validation platform to explore the new space of anti-aging solutions.”

Under the terms of the agreement, Insilico Medicine will receive an upfront payment and milestone payments upon achievement of specified goals. Insilico Medicine will be responsible for early research phase target identification and molecular generation and Taisho will work collaboratively with Insilico in validating the results in various in vitro and in vivo assays.

In addition, Taisho has the exclusive option to acquire Insilico’s co-ownership of the successfully developed programmes under agreed payment.

“It is our great honour to be collaborating with the scientists of Taisho Pharmaceutical, one of the top 100 pharmaceutical companies in the world operating since 1912,” said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.

“The high level of the scientists we are interfacing, and our previous successes in the application of the Pharma.AI platform for discovery of novel targets and molecules in fibrosis, and previous experience in senolytic drug discovery give us confidence that this collaboration will be successful,” Zhavoronkov added.

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
OneSkin

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

NAD+ and metformin: AgelessRx’s anti-aging platform

Personalised longevity medicine is the top goal for AgelessRx. In November we spoke to Anar Isman, the Co-founder & CEO of AgelessRx, about PEARL, the...
Apollo Neuro

Related articles

Plastic surgery in-a-box: a cryo biotech innovation

Future-facing Uvence is innovating for the future of your face. The biotech market is growing, as coverage on Longevity.Technology evidences. The ripples of biotech innovation...

AgeX and LyGenesis to negotiate merger agreement

The biotech merger between AgeX and LyGenesis will neaten-up Juvenescence's portfolio. AgeX Therapeutics, a biotech developing therapeutics for human aging and cell regeneration, and LyGenesis,...

Rejuvenate Biomed bags €3.2m for healthy aging R&D

Belgium biotech secures €3.2m Series A to advance the development of healthy aging products. Rejuvenate Biomed, which is based in Antwerp, has announced it has...

OneSkin: turning back time for your skin

Skin rejuvenating cream goes more than skin deep with senotherapeutic treatment. Last year we reported on the launch of OneSkin, a topical senotherapeutic skin treatment...

BioAge kicks off Phase 2 longevity clinical trial

Company reveals primary indicator for BGE-117 clinical trial is unexplained anaemia of aging. Hot on the heels of its monster $90 million Series C funding...
OneSkin